Results 221 to 230 of about 9,447,834 (313)
Nationwide Survey of Atopic Myelitis and Plexin D1‐Immunoglobulin G‐Related Pain
ABSTRACT Objective To elucidate the features of plexin D1‐immunoglobulin (Ig)G‐associated neuropathic pain and its relationship to atopic myelitis (AM) in a nationwide Japanese survey. Methods A preliminary survey questionnaire was sent to 1574 selected departments (neurology and pediatrics/pediatric neurology) to explore the numbers of AM and plexin ...
Jun‐ichi Kira +10 more
wiley +1 more source
The H10 high power density hall thruster. [PDF]
Hofer RR +4 more
europepmc +1 more source
ABSTRACT Objective To compare the effectiveness and safety of tenecteplase (TNK) versus alteplase (TPA) in patients with basilar artery occlusion prior to endovascular treatment (EVT). Methods In this retrospective multicenter study (BAO‐TNK), we analyzed consecutive BAO patients from 14 U.S.
Rahul R. Karamchandani +38 more
wiley +1 more source
Feasibility of Hybriding Very High-Power Short-Duration and Ablation Index-Guided Pulmonary Vein Isolation. [PDF]
Lee KH +6 more
europepmc +1 more source
Coupled thermal-fluid-structure behavior of airflow over target irradiated by high-power laser
Yihui Huang +2 more
openalex +2 more sources
Network Localization of Fatigue in Multiple Sclerosis
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo +12 more
wiley +1 more source
High-power laser powder bed fusion of pure copper for simultaneous achievement of high density and electrical conductivity. [PDF]
Oh WJ, Son Y, Kim DH, Kim CS.
europepmc +1 more source
DETERMINATION OF ALPHA AMYLASE AND DIASTATIC POWER IN HIGH ENZYME MALTS-COLLABORATIVE TRIAL
S. M. Sole
openalex +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source

